摘要
目的：研究抵克力得预防重组人促红细胞生成素（ｒ Ｈｕ Ｅ Ｐ Ｏ）治疗维持性血液透析患者肾性贫血所诱发的顽固性高血压和血栓症的机制和疗效。方法：将１７ 例患者随机分为两组，治疗组１０ 例，在ｒ Ｈｕ Ｅ Ｐ Ｏ 治疗同时使用抵克力得，对照组 ７ 例，只使用ｒ Ｈｕ Ｅ Ｐ Ｏ。两组均治疗 １２ 周，然后比较治疗前后两组血液学及血流动力学指标的改变及临床疗效。结果：对照组血红蛋白（ Ｈｂ）、红细胞压积（ Ｈ Ｃ Ｔ）、平均血压（ Ｍ Ｂ Ｐ）和血小板计数（ Ｂ Ｐ Ｃ）均显著升高，出血时间（ Ｂ Ｔ）、凝血时间（ Ｃ Ｔ）显著缩短，并且发生高血压和内瘘血栓形成各３ 例，而治疗组 Ｈｂ、 Ｈ Ｃ Ｔ、 Ｂ Ｐ Ｃ 也显著升高，但 Ｃ Ｔ 及 Ｍ Ｂ Ｐ无明显改变，而且 Ｂ Ｔ 显著延长，无高血压及血栓症发生。结论：抵克力得可通过改变血小板的聚集功能，减轻ｒ Ｈｕ Ｅ Ｐ Ｏ 在尿毒症患者体内引起血液学和血流动力学上的不良反应，防止ｒ Ｈｕ Ｅ Ｐ Ｏ 治疗后高血压与血栓症的发生。
Purpose: To study the mechanism and curative effect of Ticlopidine for prevention of hypertension and thrombosis induced by rHuEPO. Methods: 17 cases of uremic patients were divided into two groups at random. In therapeutic group, 10 cases received rHuEPO and Ticlopidine treatment simultaneously. In control group, 7 cases only received rHuEPO treatment. The indexes of hemology and hemodynamics were compared between before and after treatment. Results: In control group, the levels of Hb, HCT, MBP and BPC rasied obviously, the levels of BT and CT shortened, and hypertension and thrombosis occurred in 3 cases respectively. But in therapeutic group, the levels of CT and MBP unchanged, BT value prolonged, no hypertension and thrombosis occurred. Conclusions: The changes of platelet aggressive ability induced by rHuEPO may be involved in the pathogenesis of hypertension and thrombosis and Ticlopidine may effectively inhibit this process to prevent hypertension and thrombosis induced by rHuEPO.
出处
《临床泌尿外科杂志》
1999年第8期348-350,共3页
Journal of Clinical Urology
关键词
抵克力得
高血压
血栓症
RHUEPO
Ticlopidine Recombinant human erythropoietin
Hypertension Thrombosis
